Do you want to read an article? Please log in or register.
The risk of multidrug or rifampicin-resistance in men versus women with TB
Tuberculosis
RECOMMENDED
Related content
Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries
Am J Respir Crit Care Med.
Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C
doi: 10.1164/rccm.
RECOMMENDED
Tuberculosis
High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J.
Souleymane MB, Piubello A, Lawan IM, Hassane-Harouna S, Assao-Neino MM, Soumana A, Hamidou-Harouna Z, Gagara-Issoufou A, Ortuño-Gutiérrez N, Roggi A, Schwoebel V, Mamadou S, Lynen L, De Jong B, Van Deun A, Decroo T
doi: 10.1183/13993003.02250-2020.
RECOMMENDED
Tuberculosis
Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet.
Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakadis P, Lange C, Menzies D, Migliori GB, Pape JW, Palmero D, Baghei P, Tabarsi P, Viiklepp P, Vilbrun S, Walsh J, Marks SM
doi: 10.1016/S0140-6736(20)31316-7.
RECOMMENDED
Tuberculosis
Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
Lancet Infect Dis.
Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ
doi: 10.1016/S1473-3099(19)30307-X.
RECOMMENDED
Tuberculosis
Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
N Engl J Med.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills G, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M
doi: 10.1056/NEJMoa1901814.
RECOMMENDED
Tuberculosis
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
Lancet Respir Med.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R
doi: 10.1016/S2213-2600(18)30426-0.
RECOMMENDED
Tuberculosis
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017.
doi: 10.1016/S2213-2600(20)30047-3.
RECOMMENDED
Tuberculosis
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Chesov D, Heyckendorf J, Alexandru S, Donica A, Chesov E, Reiman M, Crudu V, Botnaru V, Lange C
doi: 10.1183/13993003.02544-2020
RECOMMENDED
Tuberculosis
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
Emerg Infect Dis.
Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Fréchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schünemann HJ, Lienhardt C
doi: 10.3201/eid2505.181823.